Description
CellCept, with its active ingredient mycophenolate mofetil, is primarily used for the prevention of organ rejection in patients undergoing kidney, liver, or heart transplants. It is classified under a group of medications known as immunosuppressants. CellCept works by inhibiting the proliferation of T and B lymphocytes, types of white blood cells involved in the immune response, thus reducing the body’s ability to reject a transplanted organ. It is available in various forms, including capsules, tablets, an oral suspension, and an injectable form. Given its potent immunosuppressive effects and potential for significant side effects, CellCept is prescribed under strict medical supervision.